
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris is a late-stage biopharmaceutical company that focuses on developing novel, oral bradykinin B2 receptor antagonists for the prevention and treatment of hereditary angioedema (HAE). The company's lead asset, deucrictibant, is an oral small molecule that has shown positive results in both Phase 2 prophylaxis and on-demand studies in HAE patients. Compared to currently available therapies, deucrictibant offers a more convenient and discreet oral administration, potentially increasing patient adherence and quality of life. With a strong management team and a growing HAE platform, Pharvaris is well-positioned to capture a share in the HAE market, which is expected to reach ~$4 billion by 2025. The company's ongoing pivotal Phase 3 studies for the treatment and prevention of HAE attacks, as well as its efforts to explore deucrictibant's potential in other types of angioedema, demonstrate its commitment to creating value for patients and investors. Given the positive data and potential of deucrictibant, we believe Pharvaris has strong potential for growth and market success.
Bears say
Pharvaris is currently facing multiple challenges with their late-stage biopharmaceutical product deucrictibant, including a crowded market for HAE treatments and potential safety concerns with liver enzyme elevations. The company's success may also depend on insurance coverage and pricing for their XR formulation. Additionally, their success in the AAE market is not yet proven, and dilutive financing remains a risk. As a result, the financial outlook for Pharvaris is uncertain, and it may not see the same level of success as other treatments in this space.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares